ArticleCancer cell international2026
Insulin-like growth factor-binding protein 5 promotes prostate cancer metastasis and osteoblastic activity by inducing chemokines and activating NF-κB signaling.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and validation of a machine learning-based early warning model for bone metastasis in newly diagnosed prostate cancer.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundInsulin-like growth factor binding protein 5 (IGFBP5) has been implicated in prostate cancer progression; however, its role in metastasis remains poorly defined.
methodsIGFBP5 expression and its association with clinicopathological features were evaluated using a tissue microarray containing 72 prostate tumors and 36 adjacent normal tissues. Its metastatic function was assessed through gain- and loss-of-function experiments in PC3 and DU145 prostate cancer cell lines, as well as in vivo via tail-vein injection models. To investigate bone metastasis potential, co-culture assays with osteogenic MC3T3E1 cells and endothelial tube formation assays were conducted. RNA sequencing followed by gene set enrichment analysis (GSEA) was performed to explore underlying molecular mechanisms.
resultsIGFBP5 expression was significantly elevated in prostate cancer tissues and positively correlated with higher Gleason scores. Elevated IGFBP5 levels were also associated with increased M2 macrophage infiltration (ρ = 0.514, p < 0.01) and extra-prostatic metastasis. Functional assays demonstrated that IGFBP5 overexpression enhanced epithelial–mesenchymal transition (EMT) marker expression (CDH2, vimentin, Snail), and increased cell migration and invasion, whereas IGFBP5 knockdown suppressed these aggressive phenotypes. In vivo, IGFBP5 overexpression led to a higher number of pulmonary metastatic nodules. Conditioned media from IGFBP5-overexpressing PC3 cells promoted osteogenic mineralization and endothelial tube formation, indicating pro-osteogenic and pro-angiogenic activity. Mechanistic analysis suggested that IGFBP5 facilitates metastasis through activation of NF-κB signaling, promoting EMT and upregulating chemokines such as CXCL8 and CCL2.
conclusionsIGFBP5 promotes prostate cancer metastasis by enhancing EMT, osteogenesis, and angiogenesis, potentially via NF-κB signaling. These findings highlight IGFBP5 as a promising biomarker and therapeutic target for metastatic prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.